Clinical studies with bortezomib have validated the proteasome as a therapeutic target for
the treatment of multiple myeloma and non-Hodgkin's lymphoma. However, significant …

Purpose: Carfilzomib (formerly PR-171) is a novel proteasome inhibitor of the epoxyketone
class that is selective and structurally distinct from bortezomib. Proteasome inhibition by …

Carfilzomib [(2S)-N-[(S)-1-[(S)-4-methyl-1-[(R)-2-methyloxiran-2-yl]-1-oxopentan-2-ylcarbamoyl]-2-phenylethyl]-2-[(S)-2-(2-morpholinoacetamido)-4-phenylbutanamido]-4-…

Purpose: Carfilzomib is a next-generation, selective, proteasome inhibitor with clinical activity
in relapsed and/or refractory multiple myeloma. The objectives of this phase I study were to …

C5a is a 74-amino acid glycoprotein generated on activation of the C system. The responses
evoked by C5a, both in vitro and in vivo, and its association with inflammatory diseases, …

The binding domain of the human C5a receptor consists of two distinct and physically
separable subsites. One of these sites binds the C-terminal 8 amino acids of C5a and is as yet …

Dynorphin-A-(1-8), an opioid peptide widely distributed in the rat central nervous system, is
present in vasopressin-containing neurosecretory cells terminating in the neural lobe of the …

The concentration of luteinizing hormone releasing hormone (LHRH) (pGlu‐His‐Trp‐Ser‐Tyr‐Gly‐Leu‐Arg‐Pro‐Gly‐NH
2 ), which reaches the anterior pituitary via the hypothalamo‐…

Revised Manuscript Received September 17, 1987 abstract: Rat brain metalloendopeptidase
(EC 3.4. 24.15) generates Leu-and Met-enkephalinfrom several larger opioid peptides and …

Opiate antagonists, at high doses, have been shown to improve physiological variables and
outcome after experimental spinal injury. Dynorphin appears to be unique amongst opioids …